- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Mabwell signs Albipagrastim alfa deal with Qilu Pharmaceutical | ||
| Fr | Innovent's Mazdutide receives approval for chronic weight management in China | ||
| Do | FDA approves Plus Therapeutics' Reyobiq for paediatric brain cancer | ||
| Mi | EC grants orphan drug status to JR-446 for MPS IIIB | ||
| 24.06. | Optime Care collaborates with Tilde Sciences for Vecamyl tablets | ||
| 23.06. | Archeus Technologies gets FDA approval for ART-101 application | ||
| 20.06. | CHMP endorses ExCellThera's stem cell transplantation product | ||
| 19.06. | Johnson & Johnson submits sBLA to FDA to extend use of ustekinumab | ||
| 18.06. | Ferrer's progressive supranuclear palsy therapy gains FDA fast track status | ||
| 17.06. | FDA grants fast-track status to SolasCure's gel for calciphylaxis ulcers | ||
| 16.06. | MRI and Astellas to support Japanese drug-discovery startups | ||
| 13.06. | Health Canada authorises Roche's PiaSky for PNH | ||
| 12.06. | Salipro Biotech collaborates with Daewoong for new therapies development | ||
| 11.06. | Monte Rosa Therapeutics receives FDA clearance for MRT-8102 IND | ||
| 10.06. | Neowise and BeOne Medicines sign agreement for cell therapy development | ||
| 09.06. | Italfarmaco's Duvyzat gains EC conditional approval for DMD treatment | ||
| 06.06. | Alvotech and Dr. Reddy's partner for Keytruda biosimilar | ||
| 05.06. | FDA grants breakthrough therapy status for Cellectar's iopofosine I 131 | ||
| 04.06. | Camurus and Eli Lilly collaborate on long-acting incretin products | ||
| 03.06. | Zealand Pharma submits glepaglutide MAA for short bowel syndrome | ||
| 02.06. | Mabwell's Mailisheng receives NMPA marketing approval | ||
| 30.05. | US FDA approves Alcon's Tryptyr ophthalmic solution for Dry Eye Disease | ||
| 29.05. | Archeus Technologies partners with WARF to advance ART-101 for prostate cancer | ||
| 28.05. | GRIN Therapeutics and Angelini Pharma collaborate on radiprodil development | ||
| 27.05. | Henlius receives ODD for HLX22 from European Commission |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .